title: The biology and clinical development of MEK inhibitors for cancer.
abstract: The mitogen-activated protein kinase kinases (MAPKK) MEK1 and MEK2 are integral members of the MAPK/ERK signaling pathway and are of interest in the development of anti-cancer therapeutics. The MAPK/ERK pathway is dysregulated in more than 30 % of cancers, predominately by mutations in RAS and BRAF proteins, and MEK serves as a potential downstream target for both of these. The biology of MEK inhibition is complex, as the molecule is differentially regulated by upstream RAS or RAF. This has impacted on the past development of MEK inhibitors as treatments for cancer and may be exploited in more rational, molecularly selected drug development plans in the future. The role of MEK in cancer and the mechanism of action of MEK inhibitors is reviewed. Furthermore, MEK inhibitors that are available in standard practice, as well as those most advanced in clinical development, are discussed. Finally, next steps in the development of MEK inhibitors are considered.
authors.affiliation: Melanoma and Developmental Therapeutics Clinics, University of Chicago Cancer Center, University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL, 60637, USA, jluke@medicine.bsd.uchicago.edu.
authors.forename: Jason J
authors.initials: JJ
authors.lastname: Luke
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Ott
authors.forename: Geoffrey I
authors.initials: GI
authors.lastname: Shapiro
mesh_terms: D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology; D055808:Drug Discovery / Q000379:methods; D025461:Feedback, Physiological / Q000187:drug effects*; D006801:Humans; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D048370:MAP Kinase Kinase 2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D048748:MAP Kinase Kinase Kinase 3 / Q000378:metabolism; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D048493:Proto-Oncogene Proteins B-raf / Q000378:metabolism; D035703:Therapies, Investigational; D018631:ras Proteins / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D048493:Proto-Oncogene Proteins B-raf; D048748:MAP Kinase Kinase Kinase 3; D048369:MAP Kinase Kinase 1; D048370:MAP Kinase Kinase 2; D018631:ras Proteins